IMGENEX India has a state-of-the-art R&D laboratory equipped with modern biotechnology instruments and animal house facility. Itís a scientistís delight to carry out research in cancer biology, stem cells, signal transduction, immunology, molecular biology and bioinformatics.
Delivery of osteoclast inhibitory peptides using nanotechnology-based platform for the treatment of osteoporosis is the one of the major projects at IMGENEX India. This project is being carried out by a SBIRI funding from the Department of Biotechnology, Government of India and in collaboration with the Institute of Life Sciences, Bhubaneswar.
IMGENEX India has a strong program in the development of biosimilar therapeutic monoclonal antibodies (mAbs). Our plan is to improve the efficacy of the biosimilar antibodies by encapsulating them in nanoparticles and make them as biobetters or biosuperiors, which may be defined as antibodies that are aimed at similar targets and carry similar indications as existing products, but are with improved stability and dosage.
Another area of interest for IMGENEX India is to formulate special media supplement to induce pluripotent stem cells (iPS cells) from adult somatic cells using specific proteins encapsulated in nanoparticles. These nanoparticles will allow controlled release of transcription factors in to the culture media for induction and maintenance of iPS cells from adult somatic cells. This technology will provide the ability to create patient specific iPS cells for understanding disease progression and screen for therapeutic strategies. This also alleviates the ethical issues associated with use of embryonic stem cells.